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1. Introduction 
MicroRNAs (miRNAs) are a well-established class of small (~22 nucleotides) endogenous 
non-coding RNAs that influence the stability and translation of messenger RNA (mRNA) 
(van Rooij et al., 2007). Hundreds of miRNA have been identified in numerous animal species. 
The miRNA genes are transcribed by RNA polymerase II as primary miRNA (pri-miRNA). 
The RNase III enzyme Drosha then processes the nuclear pri-miRNA, to precursor miRNA 
(pre-miRNA), which is exported from the nucleus with the help of exportin. Maturation of the 
pre-miRNA into miRNA is then mediated by the cytoplasmic enzyme Dicer, after which the 
single-stranded mature miRNA is loaded into the RNA-induced silencing complex (RISC). 
Once loaded, the miRNA guides this complex to the 3′-untranslated region (3′-UTR) of target 
mRNA (Figure 1). The socalled ‘seed region’ (nucleotides 2–8) of miRNA is most important for 
target recognition and silencing. miRNA usually binds with imperfect complementarity to its 
target, which is called the ‘seed sequence’. Association of miRNA with its target mRNA 
silences expression via at least three mechanisms: inhibition of translation, inhibition of the 
initiation of translation and destabilization of target mRNA.  
Recent advances have shown that miRNA expression during development is highly tissue-
specific, which suggests that miRNA may be involved in specifying and maintaining tissue 
identity. Recent studies have shown that a single miRNA can generate a huge impact to the 
whole profile of protein expression (Selbach et al., 2008; Baek et al., 2008). For most 
interactions, microRNAs act as ‘rheostats’ to make fine-scale adjustments to protein output 
(Baek et al., 2008). Several miRNAs have been shown to regulate the 3’-UTR of mRNA that 
encode transcription factors, and a circuit that sequentially involves miRNA and 
transcription factors in a mutual negative feedback loop has been described (Tsang et al., 
2008). The role of miRNA on protein expression, therefore, is not one-directional: from 
miRNA to protein. If we consider, however, a simple setting of miRNA and its direct target 
mRNA, the miRNA upregulated in a particular cell type from patients with specific disease 
possibly put the cell in short of a group of proteins which are necessary to maintain the 
physiological homoeostasis by targeting the translation of those proteins. In contrast, the 
miRNA downregulated in a particular cell type from patients with specific disease might 
allow the cell to increase translation of a group of proteins that are suppressed at low levels 
in normal conditions.  
In 2009, the direct involvement of single nucleotide polymorphisms of a miRNA in human 
hereditary disease was reported for the first time (Mencia et al., 2009). They found that two 
different single nucleotide polymorphisms of miR-96 are related the hearing loss found in 
two families. Their report was the start of a new era, in which the involvement of genetic  
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Fig. 1. Biogenesis of miRNA 
changes of non-coding RNAs in hereditary diseases and possibly multifactorial disorders such 
as autoimmune diseases should be considered. As we discuss in this review, our 
understanding of RA pathogenesis has been enriched by recent miRNA studies, it is now 
obvious that miRNAs play important roles in the critical aspects of RA pathogenesis such as 
joint destruction, inflammation, proliferation of synoviocytes, and chemotaxis of inflammatory 
cells. We summarize the recent advances of RA studies focusing on miRNAs, and provide the 
current understanding of the role of miRNAs in RA pathogenesis. 
2. Immunity and miRNA 
More than 100 miRNAs are expressed by cells of the immune system, and they have the 
potential to broadly influence the molecular pathways that control the development and 
function of innate and adaptive immune responses (O’Connell et al., 2010). miRNA levels 
are dynamically regulated during lineage differentiation of haematopoietic stem cells and 
also during the course of the immune response, including innate immunity and acquired 
immunity. Animal experiments of the ablating-specific miRNA genes have shown that 
miRNA expression in haematopoietic cells is critical for mounting an appropriate immune 
response. In innate immunity, miRNAs have unique effects on granulocytes, monocytes/ 
3'-UTR 
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macrophages, dendritic cells and natural killer cells. In particular, miR-146, miR-155, miR-
147, miR-21 and miR-9 have been reported to regulate the macrophage activation via a Toll-
like receptor pathway or cytokine production. miRNAs are also involved in acquired 
immunity by modulating the differentiation and function of T and B cells. miR-17-92 cluster 
targeting BIM and PTEN and miR-181a targeting DUSP5, DUSP6, SHP2 and PTPN22 are 
important for T-cell development in the thymus. For T-cell function, miR-142, miR-146, miR-
150,  miR-155, and others have been reported to regulate the development of functional T 
cells such as Th1, Th2, Th17, and Treg. 
Recently, mutant mice with a targeted deletion of miR-146a (Boldin et al., 2011) have been 
created. Baldin et al have found that miR-146a is expressed predominantly in immune 
tissues, and its expression can be induced in immune cells upon cell maturation and/or 
activation. Lack of miR-146a expression results in hyperresponsiveness of macrophages to 
bacterial Lipopolysaccharide (LPS) and leads to an exaggerated inflammatory response in 
endotoxin-challenged mice. In contrast, overexpression of miR-146a in monocytes has the 
opposite effect. Interestingly, miR-146a–null mice developed a spontaneous autoimmune 
disorder, characterized by splenomegaly, lymphadenopathy, and multiorgan inflammation, 
resulting in premature death. Using a combination of gain and loss of function approaches, 
they confirmed TRAF6 and IRAK1 genes as miR-146a targets, whose derepression in miR-
146a-null mice might account for some of the observed immune phenotypes. In addition, 
they found that miR-146a seems to play a role in the control of immune cell proliferation; 
aging miR-146a–null mice display an excessive production of myeloid cells and develop 
frank tumors in their secondary lymphoid organs, suggesting that miR-146a can function as 
a tumor suppressor in the context of the immune system. Their results showed that miR-
146a as an important negative regulator of inflammation, myeloid cell proliferation, and 
cancer. 
2.1 miRNA and Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a chronic disease of unknown cause that presents a 
characteristic inflammatory features, including synoviocyte hyperplasia, which results in 
pannus formation and joint destruction. The local production of cytokines and chemokines 
accounts for many of the pathological and clinical manifestations of RA. In culture, RA 
fibroblast like synoviocytes (FLS) proliferate and secrete a variety of cytokines/ 
chemokines/angiogenic factors, including fibroblast growth factor, granulocyte-
macrophage colony stimulating factor, interleukin 6 (IL-6), IL-8, monocyte chemoattractant 
protein 1 (MCP-1) and macrophage inflammatory proteins 1ǂ, and they present various 
adhesion molecules on their surfaces. Since the first report by Stanczyk et al in 2008, several 
reports have described the altered miRNAs in the joint and/or peripheral blood leucocytes 
of patients with RA, including miR-155, miR-146 and others (Table 1) ( Stanczyk, et al., 2008; 
Nakasa, et al., 2008; Pauley, et al., 2008; Murata, et al., 2010; Li, et al., 2010; Fulci, et al., 2010; 
Nakamachi, et al., 2009. Niimoto, et al., 2010).  
2.1.1 Overexpressed miRNAs in RA 
Stanczyk et al reported that constitutive expression of miR-155 and miR-146a was higher in 
RA synovial fibroblasts (RASF) than in those from patients with osteoarthritis (OA), and 
expression of miR-155 was induced by tumour necrosis factor ǂ (TNF-ǂ), IL-1ǃ, LPS, 
polyinosinic/polycytidylic acid. Enforced expression of miR-155 in RASF was found to 
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repress the levels of matrix metalloproteinase 3 (MMP-3) and reduce the induction of MMP-
3 and MMP-1 by Toll-like receptor ligands and cytokines. Moreover, RA synovial fluid 
monocytes displayed higher levels of miR-155 than peripheral blood monocytes. Nakasa et al 
reported that miR-146 is expressed in RA synovial tissue and its expression is induced by 
stimulation with TNF-ǂ and IL-1ǃ. They also showed by in situ hybridisation that CD68-
positive macrophages and CD3 T cells strongly express miR-146 (Nakasa et al., 2008). Pauley 
et al reported that peripheral blood mononuclear cells (PBMCs) from patients with RA 
exhibit significantly increased expression levels of miR-16, miR-132, miR-155 and miR-146a 
compared with healthy and disease control individuals (Pauley et al., 2008). Furthermore, 
they demonstrated that high levels of miR-16 and miR-146a expression correlated with 
active disease. Although miR-146a expression is increased in patients with RA, levels of the 
two established miR-146a targets, TNF receptor-associated factor 6 (TRAF-6) and IL-1 
receptor-associated kinase 1(IRAK-1), in patients with RA are similar to those in control 
individuals. Recently, Murata et al reported that synovial fluid concentrations of miR-16, 
miR-146a miR-155 and miR-223 in patients with RA were significantly higher than those in 
patients with OA. In addition, plasma miRNAs or ratio of synovial fluid miRNAs to plasma 
miRNAs, including miR-16 and miR-146a, significantly correlated with tender joint counts 
and 28-joint Disease Activity Score (DAS-28) (Murata et al., 2010).  
 
Upregulated miRNA Downregulated 
miRNA 
tissue Ref. 
miR-146, miR-155  SF Stanczyk et al, 2008 
miR-146  ST Nakasa et al, 2008 
miR-16, miR-132, miR-146a, miR-155  PBMC Pauley et al, 2008 
miR-16, miR-146a, miR-155, miR-223  JF Murata et al, 2010 
miR-146a miR-363, miR-498 CD4T Li et al, 2010 
miR-223  CD4T Fulci et al, 2010 
Let-7a, miR-26, miR-146a/b, miR-150, 
miR-155 
 IL-17+CD4 T Niimoto et al, 2010 
miR-133a, miR-146a, miR-142-3p, 
miR-142-5p, miR-223 
miR-124a SF Nakamachi et al, 
2009 
SF: Synival fibroblast, ST: Synovial tissue, PBMC: Peripheral blood mononuclear cell, JF: Joint fluid, 
CD4T: peripheral blood CD4+T cells. 
Table 1. miRNA expression in Rheumatoid Arthritis 
These studies showed that miR-146 is strongly expressed in synovial fibroblasts and 
mononuclear cells from patients with RA. Li et al reported that the level of miR-146a 
expression was positively correlated with levels of TNF-ǂ, and in vitro studies showed that 
TNF-ǂ upregulated miR-146a expression in T cells (Li et al., 2010). They also reported that 
miR-146a overexpression was found to suppress Jurkat T-cell apoptosis. Interestingly, 
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transcriptome analysis of miR-146a overexpression in T cells identified Fas associated factor 
1 as a miR-146a-regulated gene, which was critically involved in modulating T-cell 
apoptosis. Niimoto et al reported that six miRNAs, let-7a, miR-26, miR-146a/b, miR-150, and 
miR-155 were significantly upregulated in the IL-17 producing CD4+ T cells from RA 
patient (Niimoto et al, 2010). miR-146a was intensely expressed in RA synovium in 
comparison to OA. miR-146a expressed intensely in the synovium with hyperplasia and 
high expression of IL-17 from the patients with high disease activity. Double staining 
revealed that miR-146a was expressed in IL-17 expressing cells. These results indicated that 
miR-146a was associated with IL-17 expression in the PBMC and synovium in RA patients. 
Recently, Nasaka et al reported that the number of TRAP-positive multinucleated cells in 
human PBMCs was significantly reduced by miR-146a in a dose-dependent manner when 
isolated PBMCs from healthy volunteers were transfected with double-stranded miR-146a 
and cultured in the presence of M-CSF and either TNF-ǂ or RANKL (Nasaka et al., 2011). 
The expression of c-Jun, NF-ATc1, PU.1, and TRAP in PBMCs was significantly down-
regulated by miR-146a. Their results suggest that miR-146a might suppress the 
osteoclastgenesis form human monocytes. Thus, our knowledge about the roles of miR-146a 
has been expanding to various cell types including not only synoviocytes, monocytes, 
lymphocytes but also differentiated functional cells such as Th17 cells and osteoclasts.  
Taken together, several miRNAs have been repeatedlydescribed as upregulated in RA 
studies. Among those, the most redundant miRNA has been miR-146 and miR-155. 
Interestingly, miR-146 is downregulated in PBMCs from patients with systemic lupus 
erythematosus (SLE) (Tsang et al., 2009). This contrast is attractive in illustrating a difference 
in the cytokine profiles of RA and SLE, with type I interferon playing a dominant role in 
SLE, whereas TNF-ǂ, IL-1 and IL-6 are the principal cytokines in RA (Chan et al., 2009). 
2.1.2 Manipulation of overexpressed miRNAs in arthritis models 
Several groups have been focused on particular miRNAs upregulated in human RA tissues.  
They downregulated those upregulated miRNAs in human RA by targeting miRNA 
expression in mouse models of inflammatory arthritis and examined if the suppression of 
those miRNAs could regulate the arthritis development. Nasaka et al reported that 
administration of miR-146a prevented joint destruction in mice with collagen-induced 
arthritis (CIA) when double-stranded miR-146a or nonspecific double-stranded RNA was 
administered twice by intravenous injection, although it did not completely ameliorate 
inflammation (Nasaka et al., 2011). Their results indicate that expression of miR-146a 
inhibits osteoclastogenesis and that administration of double-stranded miR-146a prevents 
joint destruction in arthritic mice. Blüml et al examined the role of miRNA in the 
pathogenesis of autoimmune arthritis, using CIA and K/BxN serum-transfer arthritis in 
wild-type (WT) and miR-155-null mice (Blüml et al, 2011). They found that the miR-155-null 
mice did not develop CIA. Deficiency in miR-155 prevented the generation of pathogenic 
autoreactive B and T cells, since anti-collagen antibodies and the expression levels of 
antigen-specific T cells were strongly reduced in miR-155-null mice. Moreover, Th17 
polarization of miR-155-null mouse T cells was impaired, as shown by a significant decrease 
in the levels of IL-17 and IL-22. In the K/BxN serum-transfer arthritis model, which only 
depends on innate effector mechanisms, miR-155-null mice showed significantly reduced 
local bone destruction, attributed to reduced generation of osteoclasts, although the severity 
of joint inflammation was similar to that in WT mice. They concluded that miR-155 is 
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essentially involved in the adaptive and innate immune reactions leading to autoimmune 
arthritis. These two reports implicate that the manipulation of overexpressed miRNAs in 
PBMCs or synoviocytes such as miR-146a and miR-155, may provide a novel target for the 
treatment of patients with RA. 
2.1.3 Suppressed miRNA in RA 
There have been two reports regarding the suppressed miRNAs in RA. Li et al reported 
that miR-146a expression was significantly upregulated while miR-363 and miR-498 were 
downregulated in CD4+ T cells of RA patients (Li et al., 2010). However, their analyses 
were focused on miR-146a but not on miR-363 and miR-498. We compared synovial 
fibroblast derived from patients with RA (RASF) with those from patients with OA 
(OASF) for their expression of a panel of 156 miRNAs with quantitative stem-loop RT-
RCR (Nakamachi et al., 2009). We found that the miR-124a level significantly decreased in 
RASF. Five other miRNAs (miR-146a, miR-223, miR-142-3p, miR-142-5p and miR-133a) 
were, on the other hand, expressed more strongly in RA than in OA. In published reports, 
the expression of miR-124a has been restricted to the brain and nerve tissues of animals 
and insects (Kloosterman et al., 2006). In those tissues, miR-124a contributes to the 
differentiation of neural progenitors into mature neurons through degradation of non-
neuronal transcripts. In addition to neural tissue development, miR-124a also appears to 
be involved in carcinogenesis (Agirre et al., 2009). 
To investigate the function of miR-124a in RA, we started with the transfection of precursor 
miR-124a (pre-miR-124a) into RASF and it significantly suppressed their proliferation and 
arrested the cell cycle at the G1 phase. Interestingly, transfection with pre-miR-124a 
suppressed proliferation of RASF, but did not induce cell death. These results suggest that 
the low expression of miR-124a in RASF might protect them from cell-cycle arrest, thereby 
promoting cell proliferation. For comparison, we transfected pre-miR-146a, pre-miR-223, 
premiR-142-3p and pre-miR-133a, all of which were elevated in RASF, into OASF, but 
transfection of these pre-miRNAs did not promote the proliferation of OASF. 
A computer search with miRanda 3.0 database ( http://microrna.sanger.ac.uk/ ) to find 
possible target mRNAs for miR-124a binding in the 3′-UTR, identified a putative consensus 
site in cyclin-dependent kinase 2 (CDK-2) mRNA. The induction of precursor miR-124a 
(pre-miR-124a) in RA synoviocytes significantly suppressed the production of the CDK-2 
proteins. A luciferase reporter assay demonstrated that miR-124a specifically suppressed the 
reporter activity driven by the 3′-UTR of CDK-2 mRNA but not reporters driven by the 
mutant of 3′-UTR of CDK-2 mRNA. We also found that CDK-6 protein, another CDK that 
regulates the G1-S phase, was suppressed by miR-124a. These results suggest that miR-124a 
has a key role in regulating the proliferation of RASF. Based on these results, we assumed 
that the suppressed expression of miR-124a resulted in high expression of a group of 
proteins, especiallycell-cycle-related proteins. We next measured the levels of 
cytokines/chemokines in culture medium conditioned with RASF after overexpression of 
miR-124a, and we detected changes in the levels of three of them: MCP-1, angiogenin and 
vascular endothelial growth factor (VEGF). While VEGF levels were increased compared 
with those in medium conditioned with control cells, MCP-1 and angiogenin levels were 
significantly decreased in the presence of miR-124a overexpression. We also transfected 
precursors of miR-133a, miR-142-3p, miR-146a and miR-223 into OASF and analysed the 
culture media for cytokines/chemokines. 
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Fig. 2. The role of miRNAs in RASF 
In contrast to the findings with pre-miR-124a, the overexpression of these pre-miRNAs did 
not stimulate any cytokine/chemokine secretion from OASF. We then used the miRanda 3.0 
database to search for the 3′-UTR sequences of the mRNA encoding MCP-1, angiogenin and 
VEGF, and found that only MCP-1 mRNA contained a seed sequence for miR-124a. 
Subsequent luciferase assays showed that miR-124a specifically suppressed the luciferase 
activity driven by the 3′-UTR of MCP-1 mRNA. To elucidate the question what kind of 
stimulants depress the expression of miR-124a, we treated RASF and OASF with TNF-ǂ, IL-
1ǃ, IL-6, IL-12, IL-17, IL-18, interferon ǂ or lipopolysaccharide. However, none of these 
mediators elicited a change in miR-124a level. Possibly this unresponsiveness is the result of 
the silencing by hypermethylation of miR-124a loci, since the loci in cancer cell lines have 
been reported to be hypermethylated (Lujambio et al., 2007). Demethylation treatment with 
5-aza-2′-cytidine (5-azaC) did not suppress the proliferation of RASF, and methylation-
sensitive PCR revealed that the CpG islands of miR-124a loci in RASF were not methylated 
(Nakamachi Y, unpublished data, 2009). The hypomethylated status of miR-124a loci reflects 
the suggestion of Karouzakis et al that genes are frequently hypomethylated in RA 
(Karouzakis et al., 2009). At present, the search for factors or epigenetic events that can 
induce the suppression of miR-124a in RA pathogenesis is underway.  
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2.2 Polymorphism of miRNA and its target mRNA in RA 
RA is clinically heterogeneous, but two disease subgroups of RA can now be clearly defined 
according to the presence or absence of auto-antibodies against citrullinated proteins 
(ACPA) (Klareskog et al., 2009). Recently, thanks to genome-wide association (GWA) 
studies to analyze the genetic predisposition to RA, many susceptibility loci such as 
PTPN22, TRAF1-C5, OLIG3-TNFAIP3, CD40, CCL21 and STAT4 have been identified in 
addition to the well established HLA-DRB1 shared epitope alleles (Stahl et al., 2010). Now, 
evidence emerges of the existence of different genetic backgrounds and immune-response 
pathways contributing to the development of RA in ACPA-positive and ACPA-negative 
subgroups of patients. The interruption of miRNAs in the arena of gene regulatory networks 
has triggered interest from geneticists for looking at naturally occurring miRSNP, a SNP 
located at or near a miRNA binding site in 3’-UTR of the target gene or in a miRNA (Ryan et 
al., 2010). Martin et al demonstrated that the +1166 A/C polymorphism occurs in the 3’-UTR 
of the human AT1R( angiotensin II type 1 receptor) gene that has been associated with 
cardiovascular disease, possibly as a result of enhanced AT1R activity, for unknown reason 
(Martin et al., 2007). They assume that the +1166 A/C polymorphism disrupts the 
basepairing complementarity and the ability of miR-155 to interact, thus alleviating miR-
155-mediated repression of AT1R translation, and leading to AT1R over-expression, and 
possibly to cardiovascular disease. Several other examples of miRSNP are now reported.  
There is an only one report analyzing the polymorphism of miRNA and its associated gene 
in RA. Chatzikyriakidou et al investigated the potential association of the miR-146a variant 
rs2910164 and the two polymorphisms located in the 3’-UTR of IRAK-1 gene (rs3027898 and 
rs1059703), a known target for miR-146a, with RA susceptibility (Chatzikyriakidou et al., 
2010). Using cohorts of 136 RA patients and of 147 healthy donors, the authors found a 
significant difference in the distribution of IRAK-1 rs3027898 A>C genotypes between RA 
patients and controls. The same association was recently reported by the authors for 
psoriasic arthritis and ankylosing spondylitis (PsA) (Chatzikyriakidou et al., 2009) and by 
others for atherothrombotic cerebral infraction (Yamada et al., 2008). However, no difference 
was observed in the distribution of IRAK-1 rs1059703 and miR-146a rs2910164 variants 
between RA and control individuals. Thus, no miRSNP has yet been found functionally 
associated with RA. Therefore, it would be of real interest to assess whether the observed 
polymorphism has potential consequences on IRAK-1 expression levels and to link a 
mutation in the 3’-UTR of IRAK-1 with putative binding site for other miRNAs than miR-
146a. Another track would be to search for 3'-UTR motif(s) located in the vicinity of the 
miRNA target sequence, which may be coupled to regulation by miRNA, as it is suggested 
by a recent publication (Jacobsen et al., 2010).  
Finally, although five groups have published since 2008 that miR-146a is over-expressed in 
RA tissues; it is not a RA-specific miRNA, as it has been found deregulated in many other 
human disorders. There is thus much room for studies identifying at RA-specific miRNAs 
and investigating the impact of miRSNPs on RA in particular and on human pathologies in 
general for the next decade. 
2.3 Epigenetics of miRNA in RA 
Another important and emerging field of study for autoimmune diseases, including RA, is 
represented by epigenetics. The three main mechanisms of epigenetic control (DNA 
methylation, histone modifications, and miRNA regulation) interact in the development of 
the RA-synovial fibroblast phenotype (Karouzakis et al., 2009a). RA synoviocytes show 
www.intechopen.com
 
The Role of miRNA in Rheumatoid Arthritis 179 
epigenetic abnormalities, mainly represented by DNA hypomethylation and histone 
hyperacetylation, thus leading to synovial proliferation (Brooks et al., 2010). In RA synovial 
cells overexpression of histone deacetylase  has been demonstrated at the transcriptional 
level, and the use of histone deacetylase small-interfering RNA has revealed that this 
enzyme plays an important role in the synoviocyte proliferation and apoptosis (Horiuchi et 
al., 2009). Another study showed that synoviocyte hyperacetylation was associated with an 
increase of histone acetyl transferases, without variation of the histone deacetylases (Huber 
et al., 2007). DNA hypomethylation is another epigenetic modification that can occur in RA, 
leading to the up-regulation of genes coding for growth factors, receptors, adhesion 
molecules, and other components responsible for the inflammatory milieu and active 
phenotype of RASFs (Karouzakis et al., 2009b).  
PCR–based screening of 260 individual miRNAs which were differentially expressed 
miRNAs in RASF versus OASF revealed that expression of miR-203 was higher in RASF 
than in OASF or fibroblasts from healthy donors (Stanczyk et al., 2011). Levels of miR-203 
did not change upon stimulation with IL-1, TNF-, or LPS; however, DNA demethylation 
with 5-azaC increased the expression of miR-203. Enforced expression of miR-203 led to 
significantly increased levels of MMP-1 and IL-6. Induction of IL-6 by miR-203 
overexpression was inhibited by blocking of the NF-B pathway. Basal expression levels of 
IL-6 correlated with basal expression levels of miR-203. These results showed that the 
production of miR-223 exerts its role as a pro-inflammatory miRNA in response to the signal 
via NFB pathway and its level is influenced by methylation/ demethylation status. These 
observations show that epigenetic control is deficient in RA joint cells, suggesting that 
broader analysis is required to better understand the role of these mechanisms in the 
pathogenesis of RA, the identification of epigenetic biomarkers, and the development of 
specific therapies targeting key molecules of the epigenetic process. 
3. Biomarkers for RA 
A biomarker is a physical sign or cellular, biochemical, molecular or genetic alteration by 
which a normal or abnormal biologic process can be recognized or monitored, or both, and 
that might have diagnostic or prognostic utility (Illei et al., 2004). Biomarkers have several 
potential applications in rheumatic diseases. Genetic markers can predict or quantify the 
risk or the severity of diseases in populations or individuals. Classical examples include the 
increased risk of ankylosing spondylitis in carriers of the HLA‑B27 allele (Thomas and 
Brown, 2010), and the association between the ‘shared epitope’ and RA (de Vries et al., 
2005). An increasing number of genetic polymorphisms have been identified as risk factors 
for autoimmune diseases in general (Gregersen and Olsson, 2009; Mackay, 2009) as well as 
for specific diseases (Scofield, 2009). Autoantibodies are frequently used to establish or 
confirm a diagnosis. Some, such as anti-cyclic citrullinated peptide (CCP) antibodies in RA, 
are fairly specific for a particular disease, whereas others, such as antinuclear antibodies and 
anti-Ro (SS-A) antibody are present, albeit at different frequencies and levels, in a number of 
conditions (Schulte-Pelkum et al., 2009).  
Once a diagnosis is established, some biomarkers provide prognostic information regarding 
disease progression and severity. For example, the combination of anti-CCP antibody 
positivity and the presence of the shared epitope defines a subset of patients with a severe 
form of RA (Kaltenhauser et al., 2007; Sanmarti et al., 2007), whereas the presence of specific 
autoantibodies define distinct subsets of inflammatory myopathies (Gunawardena et al., 
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2009). Other biomarkers are used to monitor the degree of immunologic activity or 
inflammation. Measures of levels of complement activation and of anti-double stranded 
DNA autoantibodies are commonly used to monitor disease activity in lupus nephritis, and 
nonspecific markers of inflammation, such as the erythrocyte sedimentation rate or CRP 
levels, are measured in many diseases. Some of the biggest challenges, especially in the late 
stages of most chronic rheumatic diseases, include distinguishing between ongoing 
inflammation and irreversible organ damage, and assessing the impact of comorbidities or 
the adverse effects of treatments. Probably most needed are biomarkers that predict 
response to a particular therapy. Such markers could be used to optimize the risk to benefit 
ratio of a treatment in individual patients. If a strong correlation between a biomarker and a 
change in clinical activity can be established, a biomarker could act as a surrogate marker of 
a clinically important end point. Monitoring that surrogate end point could permit the use 
of targeted preemptive therapy if the measurement predicts relapse, or could be used as a 
guide to discontinue therapy if it denotes remission. 
3.1 Detection of miRNAs in body fluids 
Since 2008, several studies have evidenced the possibility of detecting miRNAs in body 
fluids including serum, plasma, urine, saliva, tears, amniotic and placental fluids, thus 
opening up major opportunities for a novel type of diagnostic molecules (Chen et al., 2008; 
Gilad et al., 2008; Mitchell et al., 2008). Since RA is a systemic chronic inflammatory disorder 
for which peripheral blood gene expression signature has been reported and molecular 
biomarkers are of great interest, identification of miRNA-based signatures is indeed a major 
issue. Most of the studies supporting the clinical utility of miRNAs as biomarkers in body 
fluids or diseased tissues have been conducted in cancer. High concentrations of cell-free 
miRNAs originating from the primary tumour have been found in the plasma of cancer 
patients, and several lines of evidence indicate that circulating miRNAs represent a 
promising source of cancer biomarkers (White et al., 2010). Indeed, correlations between 
miRNA expression levels and the development of malignancies, disease severity and 
aggressiveness, metastatic potential, therapeutic response and survival are reported in various 
cancer types. Interestingly, tumour-associated miRNomes appear highly tissue-specific. 
The detection of miRNAs in serum was quite unexpected as RNA molecules are unstable in 
the circulation. Studies (Chen et al., 2008; Mitchell et al., 2008; Mraz et al., 2009) showed that 
miRNAs exhibit high stability in the serum and plasma as they circulate within membrane 
vesicles such as exosomes or microparticles which protect them from endogenous RNase 
activity (Hunter et al., 2008). These microvesicles are resistant to drastic conditions and 
express tissue-specific markers. Although it is easily accessible and of great interest for new 
biomarker discovery, very few studies report the optimisation of extraction and detection of 
miRNAs in plasma or serum (Gilad et al., 2008; Mitchell et al., 2008). Several technical 
challenges in miRNA extraction, detection and quantification in serum or plasma are still 
underinvestigated. Moreover, all the miRNAs detected in total blood samples are not found 
in serum or plasma, and/or the low concentration of most of the miRNAs in serum or 
plasma precludes their detection, thus limiting the panel of miRNAs for solid profiling. 
Indeed, it is currently estimated that 20 miRNAs are needed for solid definition of 
biomarker signatures. For all these reasons, and mainly technical reasons, whole blood 
profiling is to be definitively the main focus in future studies on biomarker discovery, as 
opposed to plasma- or serum-based signatures. Although it seems to be very close, many 
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more studies are needed before the use of miRNAs can fulfil criteria for their use as reliable 
tools in diagnostic and prognostic settings. 
3.2 miRNAs as biomarkers for RA management 
Although the potential value of miRNAs as molecular biomarkers for diagnosis, prognosis, 
and prediction of therapeutic response is widely documented in cancer, it is still largely 
unexplored in RA. The identification of abnormal miRNA expression in the circulation or 
inflamed joints of RA patients is still in its beginning. Until now there has been only one 
publication in which the concentrations of 5 miRNAs in RA patients’ body fluids were 
measured, bringing the first proof for the use of miRNA biomarker potential in RA (Murata 
et al., 2010). In the report, synovial fluid miRNAs were present and as stable as plasma 
miRNAs for storage at -20°C and freeze-thawing from -20°C to 4°C. In RA and OA, synovial 
fluid concentrations of miR-16, miR-132, miR-146a, and miR-223 were significantly lower 
than their plasma concentrations, and there were no correlation between plasma and 
synovial fluid miRNAs. Interestingly, synovial tissues, fibroblast-like synoviocytes, and 
mononuclear cells secreted miRNAs in distinct patterns. The expression patterns of miRNAs 
in synovial fluid of OA were similar to miRNAs produced by synovial tissues. Plasma miR-
132 of healthy controls (HC) was significantly higher than that of RA or OA. Synovial fluid 
concentrations of miR-16, miR-146a miR-155 and miR-223 of RA were significantly higher 
than those of OA. Plasma miRNAs or ratio of synovial fluid miRNAs to plasma miRNAs, 
including miR-16 and miR-146a, significantly correlated with tender joint counts and DAS-
28. Therefore, plasma miRNAs had distinct patterns from synovial fluid miRNAs, which 
appeared to originate from synovial tissue. Plasma miR-132 well differentiated HC from 
patients with RA or OA, while synovial fluid miRNAs differentiated RA and OA. 
Furthermore, plasma miRNAs correlated with the disease activities of RA. Thus, synovial 
fluid and plasma miRNAs have potential as diagnostic biomarkers for RA and OA and as a 
tool for the analysis of their pathogenesis. However, this study shows that only miR-132 
plasma concentrations were significantly lower in RA than in HC, but certainly not useful as 
diagnostic biomarkers since miR-132 plasma concentrations were not correlated with DAS28 
and not disease-specific, since miR-132 plasma concentrations were also significantly lower 
in OA than in HC. Further investigations are required to find more suitable miRNAs for 
utilizing as biomarkers for diagnosis, predicting drug efficacy in order to plan optimal 
management of RA patients. 
4. Conclusion 
Our understanding of RA pathogenesis has been enriched by recent miRNA studies. We 
modified the schematic diagram described by Furer et al (Furer et al., 2010) to explain the 
mechanism of miRNA in RASF in Figure 2. It is obvious that miRNAs have important roles 
in the critical aspects of RA pathogenesis such as joint destruction, inflammation, 
proliferation of synoviocytes, and chemotaxis of inflammatory cells. Taking the involvement 
of miRNAs in leucocyte functions into account, miRNA has become one of necessary tools 
to address many unanswered questions as well as to envision the whole story of RA 
pathogenesis. It has been proposed that a gene transfer system which provides a direct 
delivery of nucleic acid into an affected joint may be useful for RNA therapy (Adriaansen et 
al., 2006). Therefore, developing a method for direct and selective transfer of specific 
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miRNA or inhibitor of miRNA into lymphocyte, synovial fibroblast, or DC may be a 
possible candidate for future treatment of RA rather than a systemic administration of 
miRNA which may cause off-target or harmful effects to different tissues and cell types. 
In the meantime, miR-124a is unique in that it is downregulated in RASF and directly 
associated with cell-cycle regulation. When you consider the proliferative nature of RASF, 
miR-124a may have a good candidacy for a novel drug for RA treatment. Therefore, 
developing a drug delivery system for direct and selective transfer of miR-124a into RASF, 
such as intra-articular injection, is an attractive idea, since systemic administration of miR-
124a may possibly cause ‘off-target effects’ or harmful side effects on different tissues and 
cell types. Besides the miRNAs described in this article, it is expected that new biomarkers 
and therapeutic tools will be developed in the near future based on the research generated 
from miRNAs. 
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source of potential areas of investigation for research scientists working in the field of RA and other
inflammatory arthropathies.
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